◀ Back to EPO
EPO — TGFB1
Text-mined interactions from Literome
Logofetov et al., Arch Physiol Biochem 1998
(Anemia...) :
Single dose recombinant human
erythropoietin reduces
transforming growth factor beta in patients on chronic haemodialysis ... Short-term
effects of recombinant human
erythropoietin on serum levels of
transforming growth factor beta-1 , interleukin 1-alpha, interleukin 3, interferon gamma, and tumour necrosis factor alpha in patients with chronic renal failure on chronic haemodialysis were investigated
Zermati et al., Exp Hematol 2000
:
When UT-7 cells were switched from GM-CSF to
Epo ,
TGF-beta1 ( 2 ng/mL )
induced a rapid ( 3 days [ Epo+TGF-beta1 ] vs 8 days [ Epo ] ) and marked erythroid differentiation ( 80 % [ Epo+TGF-beta1 ] vs 10 % [ Epo ] BPC ) including Hemoglobin A synthesis ( HbA/HbF ratio of 1 [ Epo ] vs 4 [ Epo+TGF-beta1 ] )
Zhang et al., Zhonghua Xin Xue Guan Bing Za Zhi 2008
:
The present experiment was designed to investigate the
effects of
EPO on
TGF-beta1 , nitric oxide synthase (NOS), collagen contents induced by angiotensin II (Ang II) in rat cardiac fibroblasts ( CFs ) and explore the roles of PI3-K/Akt signaling pathway on related effects
Wen et al., Scand J Clin Lab Invest 2009
(Cardiomegaly) :
EPO also
down-regulated the protein expression of
TGF-beta1
Chen et al., Exp Cell Res 2010
:
We examined the
effect of
EPO on
TGF-beta1 mediated Smad signaling
Leveque et al., Hematol Oncol 1996
(Leukemia, Megakaryoblastic, Acute) :
TGF beta 1 also
inhibited the expression of
Epo-receptors on UT-7 cells, without changing receptor affinity